Lv3
270 积分 2023-03-14 加入
Cancer incidence and mortality in China, 2022
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
1118P Real-world adjuvant treatment patterns in patients with stage I-III EGFR-mutated non-small cell lung cancer (NSCLC) in China: Interim analysis from the ADDRESS study
1个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
1个月前
已完结
OA02.04 A Phase III Study of Rilertinib Versus Gefitinib as First-Line Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC
1个月前
已完结
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
1个月前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
1个月前
已完结
Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study
1个月前
已完结
25P Real-world treatment patterns and outcomes in the US after first-line (1L) osimertinib (osi) in patients with epidermal growth factor receptor (EGFR)-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)
1个月前
已关闭
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies
2个月前
已完结
皖公网安备34019202002308
